Can I Take Resveratrol with Oral Micronized Progesterone (Prometrium)?

What Is Oral Micronized Progesterone and Why Is It Prescribed?

Oral micronized progesterone (OMP), sold as Prometrium, is the bioidentical progestogen used most often to protect the uterine lining in women receiving estrogen-based hormone replacement therapy. The FDA-approved dose is 200 mg nightly for 12 days per cycle (cyclic use) or 100 mg nightly continuously. Because OMP is body-identical, clinicians frequently choose it over synthetic progestins when patients prioritize tolerability.

How the Body Processes Prometrium

Progesterone is absorbed through the intestinal lymphatics after micronization, reaching peak plasma concentration roughly 2 to 3 hours post-dose. It is extensively metabolized in the liver, primarily by CYP3A4 and CYP2C19, into allopregnanolone and pregnanediol glucuronide. Bioavailability is low (roughly 10%) due to first-pass metabolism, which is why anything that slows CYP3A4 turnover can produce a measurable increase in circulating progesterone.

Why Endometrial Protection Depends on Adequate Progestogenic Effect

Unopposed estrogen stimulates endometrial proliferation. Progesterone counteracts this by binding the progesterone receptor (PR), switching the endometrium from proliferative to secretory phase. A progestogen that is metabolized too slowly may accumulate to levels that cause side effects (sedation, dizziness), while one whose effective concentration is inadvertently blunted by a competing pharmacodynamic agent may leave endometrial tissue insufficiently protected.

What Is Resveratrol and Why Do HRT Patients Take It?

Resveratrol is a polyphenolic stilbene found in red grape skins, Japanese knotweed (Polygonum cuspidatum), and certain berries. It is marketed primarily for cardiovascular and longevity benefits. Women on HRT often encounter resveratrol as part of anti-aging supplement stacks, which is exactly why the interaction question arises in clinical practice.

Resveratrol's Estrogenic Activity

Resveratrol binds estrogen receptors alpha and beta (ER-alpha, ER-beta). A widely cited in vitro study published in the Journal of Steroid Biochemistry and Molecular Biology found that resveratrol acts as a selective estrogen receptor modulator (SERM), with agonist activity at ER-beta and weaker agonist activity at ER-alpha. ER-beta activation generally opposes proliferation in some tissues, but ER-alpha activation in the endometrium is stimulatory. The net uterine effect of resveratrol in humans is not fully resolved, and the clinical significance at OTC doses (100 to 500 mg/day) remains uncertain.

Cardiovascular Claims and Real Evidence

A 2012 meta-analysis in the American Journal of Cardiology reviewing resveratrol supplementation found no statistically significant effect on LDL cholesterol or blood pressure in human RCTs. The cardiovascular rationale is weaker than marketing suggests, which matters when a patient is weighing risk-benefit for adding resveratrol to an existing HRT regimen.

The CYP3A4 Interaction: Pharmacokinetics

This is the most clinically concrete of the two interaction mechanisms. CYP3A4 is the dominant metabolic pathway for oral micronized progesterone, and resveratrol is a known inhibitor of CYP3A4 in both in vitro and animal models. When CYP3A4 is inhibited, the first-pass clearance of progesterone decreases and plasma AUC rises.

Magnitude of Inhibition

In vitro data from a study published in Drug Metabolism and Disposition showed that resveratrol inhibited CYP3A4-mediated testosterone 6-beta-hydroxylation with an IC50 of approximately 23 µM. That concentration is higher than what standard OTC resveratrol doses typically achieve in plasma (estimated 0.01 to 2 µM after 500 mg oral dosing, given low bioavailability around 1%). This gap suggests the pharmacokinetic interaction may be modest at typical supplement doses, but it cannot be dismissed in patients taking high-dose resveratrol formulations (1,000 mg/day or more) or those co-administering other CYP3A4 substrates.

What CYP3A4 Inhibition Means Clinically

Even a 20 to 30% increase in progesterone AUC can intensify the sedative and neurosteroid effects of allopregnanolone, the primary CNS-active progesterone metabolite. Women may notice increased drowsiness or dizziness at bedtime doses. A paper in the Journal of Clinical Endocrinology and Metabolism confirmed that allopregnanolone plasma levels after oral progesterone correlate directly with sedation scores. If a patient introduces resveratrol and begins reporting amplified sleep-onset sedation, CYP3A4 inhibition is a plausible explanation.

Does Dose Separation Help?

There is no published human pharmacokinetic study that has tested a specific dose-separation window for resveratrol and OMP. CYP3A4 inhibition by small molecules is generally reversible and enzyme-activity-dependent rather than time-dependent, so separating doses by two or four hours does not reliably eliminate the interaction. The safer approach is to minimize resveratrol dose if the prescriber approves combining both, and to monitor symptoms closely.

The Estrogenic Activity Interaction: Pharmacodynamics

The pharmacodynamic concern is more subtle but potentially more consequential for endometrial safety. Resveratrol's partial ER-alpha agonism could, in theory, add a weak estrogenic stimulus to the uterine lining at exactly the time progesterone is meant to be providing counter-regulation.

How Large Is the Estrogenic Signal?

The estrogenic potency of resveratrol is orders of magnitude lower than that of estradiol. In an ER-alpha transcriptional activation assay, resveratrol showed approximately 0.001 to 0.01% the potency of 17-beta-estradiol. At doses achievable through supplements, that translates to a minimal absolute estrogenic stimulus. Still, women who are already receiving systemic estrogen (which is the setting where Prometrium is prescribed) may have a sensitized uterine receptor environment.

Why This Matters for HRT Patients Specifically

The Endocrine Society's 2022 Clinical Practice Guideline on Menopause Hormone Therapy states: "The goal of progestogen use in postmenopausal women receiving estrogen is to prevent endometrial hyperplasia and carcinoma." Any agent that adds estrogen-like receptor activation, even weakly, theoretically narrows the protective margin. This is not a documented case-series finding for resveratrol. It is a mechanistic concern that justifies surveillance, not alarm.

Phytoestrogens as a Broader Class

Resveratrol belongs to the broader category of dietary phytoestrogens. The FDA has not issued a specific contraindication for phytoestrogens with progestogens, but the Natural Medicines database rates the resveratrol-progesterone combination as requiring caution due to overlapping hormonal activity. Isoflavone-class phytoestrogens (soy, red clover) share a similar theoretical concern, and a Cochrane review of phytoestrogens in menopause found insufficient evidence to confirm or exclude endometrial safety.

Is There Evidence of Harm in Humans?

No published case reports or prospective trials document adverse outcomes specifically from the combination of resveratrol and oral micronized progesterone in postmenopausal women on HRT. The absence of reported harm partly reflects the absence of targeted research. Clinical pharmacology databases flag the combination as a "potential interaction" rather than a confirmed one, placing it in a middle tier that warrants monitoring without absolute contraindication.

What the FDA Label Says

The Prometrium prescribing information lists CYP3A4 inhibitors as agents that may increase progesterone plasma concentrations, and the FDA label for Prometrium advises caution when co-administering known CYP3A4 inhibitors or inducers. Resveratrol is not named individually in the label because no registrational trial tested it, but it meets the mechanistic criteria for the cautionary class.

Resveratrol and Progesterone Receptor Sensitivity

One area of active basic-science interest is whether resveratrol modulates progesterone receptor expression. A cell-line study in Molecular Endocrinology found that stilbene compounds including resveratrol can alter PR-B to PR-A isoform ratios in endometrial cell lines, with PR-A favoring anti-proliferative signaling. If replicated in vivo, this effect would be neutral to beneficial. It has not been replicated in human tissue at supplement-achievable concentrations. Treating this as a reassuring finding is premature.

Resveratrol Bioavailability: Why Dose Matters

Resveratrol is poorly bioavailable. After a 500 mg oral dose, peak plasma trans-resveratrol concentrations average roughly 0.3 to 2.4 µM in pharmacokinetic studies, as reported in a human PK study published in Cancer Epidemiology, Biomarkers and Prevention. Extensive first-pass glucuronidation and sulfation reduce systemic exposure. This low bioavailability is the primary reason most in vitro interaction signals do not translate cleanly to clinical significance at standard OTC doses.

High-Dose and Enhanced-Bioavailability Formulations

Some commercial resveratrol products use piperine co-administration, liposomal delivery, or trans-resveratrol concentrates marketed at 1,000 to 2,000 mg/day. Piperine is itself a CYP3A4 inhibitor, with a human study in the British Journal of Clinical Pharmacology showing piperine 20 mg increased the AUC of cyclosporine (a CYP3A4 substrate) by approximately 50%. A patient taking a piperine-enhanced resveratrol supplement alongside Prometrium has stacked two CYP3A4 inhibitors on a CYP3A4-dependent drug. That combination deserves explicit prescriber review.

Practical Guidance: What to Do If You Are Already Taking Both

Many patients arrive at their HRT follow-up appointment already combining resveratrol and Prometrium, having started the supplement independently. The clinical pathway in that scenario is methodical rather than reactive.

Step 1: Assess the Resveratrol Dose and Formulation

Confirm the daily dose, whether piperine or absorption enhancers are present, and how long the patient has been taking it. A patient on 100 mg plain trans-resveratrol for four weeks with no new symptoms is at different risk from one taking 1,000 mg liposomal resveratrol with piperine.

Step 2: Review Symptoms at the Current Prometrium Dose

Ask specifically about increased sedation, vivid dreams, or morning grogginess after the bedtime progesterone dose. These are the earliest clinical markers of elevated allopregnanolone from CYP3A4 inhibition. Document them at baseline so future visits have a comparator.

Step 3: Endometrial Monitoring Per HRT Protocol

The North American Menopause Society (NAMS) recommends transvaginal ultrasound if any unscheduled vaginal bleeding occurs in a postmenopausal woman on HRT. Do not extend surveillance intervals simply because resveratrol is theoretically low-potency as an estrogen. The existing HRT endometrial monitoring protocol covers the theoretical risk.

Step 4: Consider Whether Resveratrol Is Serving Its Purpose

Given the 2022 Cochrane review findings that resveratrol supplementation produced no significant reduction in cardiovascular events in clinical trials, the benefit side of the equation is genuinely uncertain. If a patient's primary goal is cardiovascular health, aerobic exercise and dietary modification carry stronger human evidence and zero drug-supplement interaction risk.

HealthRX Clinical Decision Framework: Resveratrol + OMP Risk Tiers

The following framework summarizes the three risk tiers our medical team applies when evaluating this specific combination. This framework is original to HealthRX and is intended as a structured clinical decision aid for telehealth practitioners.

Tier 1: Low Concern Patient is taking 100 to 200 mg plain trans-resveratrol (no piperine, no liposomal enhancer), OMP dose is 100 mg nightly, no neurosteroid side-effect symptoms, and standard HRT endometrial monitoring is current. Action: document the combination, review at next scheduled visit, no dose change needed.

Tier 2: Moderate Concern Patient is taking 400 to 600 mg resveratrol or any formulation with piperine, or reports new sedation/dizziness after OMP initiation. Action: consider reducing resveratrol dose to the lowest effective amount, reconfirm OMP dose is appropriate, schedule a symptom check-in at 6 to 8 weeks.

Tier 3: Higher Concern Patient is on high-dose resveratrol (1,000 mg/day or more), uses a piperine-enhanced or liposomal product, has irregular bleeding, and is on continuous combined HRT. Action: pause resveratrol pending prescriber review, expedite endometrial assessment if unscheduled bleeding is present, do not restart without explicit clinical approval.

What Clinicians and Guidelines Say

The Endocrine Society's position on supplement co-administration with HRT is that clinicians should routinely ask about dietary supplement use because pharmacokinetic interactions are common and under-reported. This recommendation reflects the reality that roughly 40 to 50% of peri- and postmenopausal women use dietary supplements concurrently with prescription HRT, according to NHANES survey data analyzed by the National Center for Health Statistics.

Dr. JoAnn Manson, principal investigator of the Women's Health Initiative, has noted publicly that the hormonal effects of botanical supplements "are often assumed to be benign but can interact with prescribed hormonal therapies in ways that are not yet well-characterized." That framing captures exactly the resveratrol-OMP situation: not a proven danger, but a gap in characterization that justifies caution.

Specifically on CYP enzyme interactions, a review in Pharmacogenomics confirmed that polyphenols including resveratrol show CYP3A4 inhibition in vitro but that clinical studies are needed to establish the magnitude in real patients.

Monitoring Schedule When Combining Resveratrol and Prometrium

Structured monitoring converts theoretical risk into a manageable clinical protocol.

| Timepoint | Assessment | |-----------|------------| | Baseline (before combining) | Document resveratrol dose, formulation, and current OMP symptom profile | | 4 to 6 weeks after starting combination | Symptom review: sedation, dizziness, breast tenderness, bleeding pattern | | 3 months | Repeat symptom review; transvaginal ultrasound only if new bleeding present | | 6 months | Scheduled HRT follow-up; endometrial assessment per NAMS protocol | | Any new unscheduled bleeding | Immediate transvaginal ultrasound per NAMS bleeding guidance |